Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00DPJ
|
||||
| Former ID |
DIB007546
|
||||
| Drug Name |
Amezinium
|
||||
| Synonyms |
Amezinium methyl sulfate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypotension [ICD9: 458, 796.3; ICD10:I95] | Approved | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H15N3O5S
|
||||
| Canonical SMILES |
COc1cc(N)cn[n+]1c2ccccc2
|
||||
| InChI |
1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
|
||||
| InChIKey |
VXROHTDSRBRJLN-UHFFFAOYSA-O
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [2], [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.